Directors' Dealings

Amphion Innovations plc

 ("Amphion" or "the Company")

Directors' DealingsDirectors Receive Shares in Lieu of Fees

London and New York, 16 September 2015 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that the Company has today issued 598,850 ordinary shares in the Company ("New Ordinary Shares"), representing 0.30% of the enlarged issued share capital, to certain of its Board members as their directors' fees for the second and third quarters of 2015, priced at 6.250 pence, being the average of the closing mid-market price for the five days leading up to the market close on 11 September 2015. Following this issue, the directors' shareholdings in the Company are as follows:

Admission of the 598,850 New Ordinary Shares, ranking pari passu with the existing ordinary shares, to trading on AIM is expected on 21 September 2015. Following this allotment the total issued share capital of the Company will increase to 197,219,423 ordinary shares with each share holding one voting right.

For further information please contact:

Amphion InnovationsCharlie Morgan+1 212 210 6224Yellow Jersey PR

Charles Goodwin / Dominic Barretto+44 (0)7747 788 221Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Freddy Crossley / Duncan Monteith (Corporate Finance)Charlie Leigh-Pemberton (Corporate Broking)+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker) Patrick Claridge / David Hignell (Corporate Finance)John Howes / Mark Treharne (Corporate Broking)+44 (0)20 7382 1100

Plumtree Capital Limited (Financial Adviser)Stephen Austin+44 (0)20 7183 2493+646 568 7502

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: www.amphionplc.com